Benchling investors & funding

Benchling has raised a total of $418M, reflecting robust confidence from investors in its market potential and growth strategy. The funding rounds have provided the necessary capital to drive innovation and scale operations in a competitive biotechnology market. The significant capital influx has allowed the company to invest heavily in R&D and market expansion. The overall funding structure is geared towards long-term strategic development.

A key milestone in Benchling's funding history was the $100M Series E round completed in April 2021. This round saw participation from prominent investors such as Artisanal Ventures, Eight Roads, Foreword, Franklin Templeton, and Franklin Venture Partners. The Series E round underscored the company’s commitment to scaling its platform and expanding its market reach. Investor confidence in Benchling is further bolstered by its strategic alignment with growth and innovation.

Investment in Benchling is also viewed as a vote of confidence in its ability to transform life sciences research through technology. The funding enables concerted efforts in product development and market penetration, ensuring competitive differentiation. Additionally, the diverse portfolio of investors provides a strategic network that supports broad market insights. 

- Key investors: Artisanal Ventures, Eight Roads, Foreword, Franklin Templeton, Franklin Venture Partners; Funding milestone: $100M Series E.